An article has been published as the third installment of the Nikkei BioTech ONLINE series, introducing the rapid rise of drug discovery originating in China and the ways it is changing the competitive structure of the global drug discovery industry. The author is Yoshida Eiji (吉田 瑛二).
This is the third installment of a series focusing on “the power to drive innovation,” and explains that China, which has risen rapidly in recent years, is the starting point. It presents the view that drug discovery originating in China could determine the competitiveness of the industry.
The article reaffirms the issue raised in the second installment concerning the “innovation lag,” in which medical innovations developed overseas fail to create value domestically, as well as the importance of the ability to incorporate innovation from around the world. It states that, as the next stage, the focus will shift to the “power to create” in drug discovery.